Pathogenic microorganisms like bacteria and fungi are a rapidly emerging, major threat to human, animal and plant life. Growing microbial resistance, population growth, global trade and increasing mobility have reinforced the need for quick, easy and simple diagnostic procedures at the point of origin in order to prevent proliferation at the earliest possible stage.
Established as a joint venture by Biosynth AG, a Swiss-based developer of reagents and biologically active chemicals, and Ramot, the Tel Aviv University Business Engagement Center, Nemis Technology developed a technology platform AquaSpark, which forms the basis for Nemis’ diagnostic kits and solutions for rapid pathogenic bacteria detection in food safety, hospital and clinical applications and water treatment.
AquaSpark enables highly sensitive chemiluminescence probes for research and diagnostic applications. Pathogenic, potentially life-threating bacteria are made visible with light signals at much faster speed than with current standard methods, thus reducing effectively important safety risks at highly competitive cost.
“Our AquaSpark technology, originally a Tel Aviv University technology licensed from Ramot, has already achieved a functional proof-of-concept that allows a much faster, cheaper and effective detection of some of the most threatening foodborne pathogens, a major threat to consumers and food companies,” says Arnaud Muller, CEO of Nemis.
Today, the company announced the closing of its 2018 seed financing round in which the investors raised CHF3 million. “We are pleased to welcome our new investors who bring in a lot of relevant industry and business expertise. Thanks to them, we will be able to advance our technology to prototypes and towards industrialization,” says Roger Meier, the Chairman of the Board. (Press release/ran)